BIAF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the data provided, bioAffinity Technologies Inc (BIAF) does not present a strong buy opportunity for a beginner investor with a long-term strategy. While the company has shown innovation in its CyPath® Lung test, the financial performance is weak, with declining revenue and negative earnings. Additionally, there are no strong trading signals or significant positive catalysts to suggest immediate upside potential.
The MACD is positive and expanding, indicating a bullish trend. RSI is neutral at 64.797, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear directional trend. Key resistance levels are at 1.295 and 1.46, while support levels are at 0.763 and 0.598.
The CyPath® Lung test demonstrates significant advancements in noninvasive cancer diagnostics with high sensitivity and specificity. This innovation could reduce the need for invasive procedures and healthcare costs, potentially driving future growth.
The company's financials are weak, with a significant YoY revenue drop (-38.48%), negative net income (-$5,051,084), and declining gross margin (-16.38%). Additionally, there are no significant hedge fund or insider trading trends, and no recent congress trading data.
In Q3 2025, the company reported a 38.48% YoY revenue decline, a net income loss of -$5,051,084 (though improved by 152.45% YoY), and a gross margin drop of 16.38%. EPS also declined by 2.07% YoY.
No analyst rating or price target data available.
